ARB 1467
Alternative Names: ARB 1468; ARB-001467; ARB-1467; TKM HBVLatest Information Update: 27 Mar 2019
At a glance
- Originator Protiva Biotherapeutics
- Developer Arbutus Biopharma
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 07 Mar 2019 Arbutus Biopharma terminates a phase II trial in Hepatitis B (Combination therapy) in Poland and Spain as the company discontinued the development of the drug and to focus on the development of next-generation RNAi agent AB 729 (IV) (EudraCT2017-001647-12)
- 31 Dec 2018 Discontinued - Phase-II for Hepatitis B (Combination therapy) in Poland (IV)
- 31 Dec 2018 Discontinued - Phase-I for Hepatitis B (In volunteers) in Canada (IV)